Pediatric Antiphospholipid Antibody Syndrome Medication
- Author: Barry L Myones, MD; Chief Editor: Lawrence K Jung, MD more...
Very few studies have addressed the efficacy of any treatment protocol in antiphospholipid antibody syndrome (APS). Most are small retrospective analyses or anecdotal reports. Many prospective studies have included too few patients and have been hampered by a lack of homogeneity of test groups. The Sapporo criteria were established, in part, to ensure a uniform homogeneous test population in order to promote accurate prospective studies of treatment protocols for patients with antiphospholipid antibody syndrome.
Aspirin inhibits prostaglandin synthesis, preventing formation of platelet-aggregating thromboxane A2. It is used in low doses to inhibit platelet aggregation and improve complications of venous stases and thrombosis. However, doses as low as 5 mg/kg appear to additionally inhibit prostacyclin, thus promoting a procoagulant state. No prevalence data on aspirin resistance in children has been reported. The effect of aspirin on platelet function can be assessed by optical platelet aggregometry or Platelet Function Analyzer (PFA-100). Ticlopidine does not inhibit cyclooxygenase and, in this way, differs from aspirin. It inhibits the primary and secondary phase of aggregation induced by adenosine 5'-diphosphate (ADP) and reduces platelet-derived growth factor. Ticlopidine may also impair platelet adhesion, resulting in prolonged bleeding time. Dipyridamole potentiates the inhibitory effects of aspirin on platelet aggregation.
Used for antiplatelet effect. Inhibits prostaglandin synthesis, preventing formation of platelet-aggregating thromboxane A2. May be used in low dose to inhibit platelet aggregation and improve complications of venous stases and thrombosis.
Used for livedoid vasculitis and thromboembolic disorders. Second-line antiplatelet therapy for patients who cannot tolerate or in whom aspirin therapy has failed.
Used for thromboembolic disorders to complement usual aspirin or warfarin therapy. Platelet adhesion inhibitor that possibly inhibits RBC uptake of adenosine, which is an inhibitor of platelet reactivity. In addition, may inhibit phosphodiesterase activity, leading to increased cyclic-3',5'-adenosine monophosphate within platelets and formation of the potent platelet-activator thromboxane A2.
Used alone or in combination with low-dose aspirin therapy as indicated above. Also used in combination with low-dose PO anticoagulant therapy (with or without aspirin) in children with mechanical prosthetic heart valves.
Unfractionated intravenous heparin and fractionated LMW subcutaneous heparin are the choices for initial anticoagulation therapy. If warfarin is chosen as maintenance therapy, it is initiated and concurrently administered with heparin for several days until the international normalized ratio (INR) reaches the target range.
Used for thromboembolic disorders. Augments activity of antithrombin III and prevents conversion of fibrinogen to fibrin. Does not actively lyse but is able to inhibit further thrombogenesis. Prevents reaccumulation of clot after spontaneous fibrinolysis. Used as a continuous infusion while initiating PO warfarin therapy.
Used for thromboembolic disorders. Prevents DVT, which may lead to PE in patients undergoing surgery who are at risk for thromboembolic complications.
Enhances inhibition of factor Xa (preferentially) and thrombin (factor IIa) by increasing antithrombin III activity. The ratio of antifactor Xa to antifactor IIa activity is approximately 4:1 (1:1 for unfractionated heparin)
Used for thromboembolic disorders. Interferes with hepatic synthesis of vitamin K–dependent coagulation factors. Used for prophylaxis and treatment of venous thrombosis, pulmonary embolism, and thromboembolic disorders.
Adjust dose to maintain an INR in the range of 2.5-3.5.
Immune globulin is a purified preparation of gamma globulin derived from large pools of human plasma. It is composed of 4 subclasses of IgG antibodies, approximating the distribution of human serum. IgA-depleted products are also low in the IgG4 component.
Used for autoimmune diseases. Neutralizes circulating myelin antibodies through antiidiotypic antibodies; down-regulates proinflammatory cytokines, including INF-gamma; blocks Fc receptors on macrophages; suppresses inducer T and B cells and augments suppressor T cells; blocks complement cascade; promotes remyelination; may increase CSF IgG (10%).
These agents are used to lower elevated blood pressure, decrease vasospasm, or prevent ischemia. Niacin is also used to decrease hyperlipidemia.
Causes relaxation of vascular smooth muscle by stimulating intracellular cyclic guanosine monophosphate production. The result is a decrease in blood pressure.
Onset of action for ointment is 20-60 min. Duration of effect is 2-12 h.
Also called nicotinic acid or vitamin B-3. Component of 2 coenzymes necessary for tissue respiration, lipid metabolism, and glycogenolysis; inhibits synthesis of VLDL. Used as a dietary supplement and as adjunctive treatment of hyperlipidemias, peripheral vascular disease, circulatory disorders, and treatment of pellagra.
Onset of action within 20 min (extended release within 1 h). Duration of effect 20-60 min (extended release 8-10 h). Half-life 45 min.
Drugs with effects on vascular endothelium, platelets, red blood cells
These drugs appear to have multiple mechanisms in the prevention of thrombosis and vascular spasm. The exact mechanisms are largely unexplained, but the properties of these drugs include changes in RBC rheology, inhibition of platelet adhesiveness/activation, inhibition of TNF-alpha production, and decreases in neutrophil and endothelial cell activation.
Used in vascular disease. May alter rheology of RBCs, which, in turn, reduces blood viscosity. Improves peripheral perfusion and vascular spasm in Raynaud phenomenon and vasculopathy/vasculitis.
Other effects include inhibition of platelet adhesiveness/activation, inhibition of TNF-alpha production, and decrease in neutrophil and endothelial cell activation.
Inhibits platelets, chemotaxis of eosinophils, and locomotion of neutrophils and impairs complement-dependent antigen-antibody reactions.
Hydroxychloroquine sulfate 200 mg is equivalent to 155 mg hydroxychloroquine base and 250 mg chloroquine phosphate.
Affects vascular beds and cardiovascular function. May improve blood flow by altering rheology of RBCs. Produces nonhomogenous dilation of vascular beds, with more dilation in femoral beds than in vertebral, carotid, or superior mesenteric arteries.
Cilostazol and its metabolites are inhibitors of phosphodiesterase III and, as a result, cyclic AMP is increased, which leads to inhibition of platelet aggregation and vasodilation.
Platelet count enhancers
These agents are used to augment platelet recovery.
Mechanism of action for treatment of thrombocytopenia is uncertain. May involve a decrease in reticuloendothelial cell function or an increase in platelet production. However, neither of these mechanisms fully explains the effect in TTP and HUS.
Synthetic steroid analog with strong antigonadotropic activity (inhibits LH and FSH) and weak androgenic action.
Increases levels of C4 component of complement and reduces attacks associated with angioedema. In hereditary angioedema, danazol increases level of deficient C1 esterase inhibitor.
Other therapy with multiple actions
Medications with vasodilatory and antiplatelet activity with specific usage in the treatment of pulmonary hypertension and/or healing of refractory skin ulcerations have been administered in patients with APS.[84, 85, 86]
Endothelin-receptor antagonist indicated for the treatment of pulmonary arterial hypertension in patients with WHO class III or class IV symptoms to improve exercise ability and decrease rate of clinical worsening. Inhibits vessel constriction and elevation of blood pressure by competitively binding to the endothelin-1 (ET-1) receptors ETA and ETB in endothelium and vascular smooth muscle. This leads to a significant increase in the cardiac index (CI) associated with significant reduction in pulmonary artery pressure (PAP), pulmonary vascular resistance (PVR), and mean right atrial pressure (RAP). Due to teratogenic potential, can only be prescribed through the Tracleer Access Program (1-866-228-3546).
Prostacyclin, PGI2 analogue that has potent vasodilatory properties. Elicits immediate onset of action. Half-life is approximately 5 min. In addition to vasodilator properties (all vascular beds), also contributes to inhibition of platelet aggregation (activates intracellular adenylate cyclase and results in increased CAMP in platelets) and plays role in inhibition of smooth muscle proliferation.
FDA-approved for pulmonary hypertension. Promotes selective smooth muscle relaxation in lung vasculature possibly by inhibiting phosphodiesterase type 5 (PDE5). This results in subsequent reduction of blood pressure in pulmonary arteries and increase in cardiac output. Elicits vasodilation and inhibits platelet aggregation. Also aids in healing refractory skin ulcerations.
Therapy for dyslipoproteinemia or hyperlipidemia may reduce vascular risk factors for thrombosis. In vitro and animal model evidence suggests decreased endothelial cell and granulocyte activation.[92, 89]
The most efficacious of the statins at high doses. Inhibits 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA reductase), which in turn inhibits cholesterol synthesis and increases cholesterol metabolism. Reports have shown as much as a 60% reduction in LDL-C. The Atorvastatin versus Revascularization Treatment study (AVERT) compared 80 mg atorvastatin daily to standard therapy and angioplasty in patients with CHD. While events at 18 mo were the same between both groups, the length of time until the first CHD event occurred was longer with aggressive LDL-C lowering. The half-life of atorvastatin and its active metabolites is longer than that of all the other statins (ie, approximately 48 h compared to 3-4 h).
May modestly elevate HDL-C levels. Clinically, reduced levels of circulating total cholesterol, LDL-C, and serum TGs are observed.
Before initiating therapy, patients should be placed on a cholesterol-lowering diet for 3-6 mo; the diet should be continued indefinitely.
Effective in reducing circulating lipid levels and improving the clinical and anatomic course of atherosclerosis.
Inhibits cholesterol synthesis and increases cholesterol metabolism.
Biological response modulator
Targeted anti-B cell therapy has been used in the treatment of refractory idiopathic thrombocytopenic purpura (ITP) postsplenectomy. The use of this modality has been extrapolated to treatment protocols for antiphospholipid syndrome.[93, 94, 95]
Indicated to reduce signs and symptoms for moderately-to-severely active rheumatoid arthritis in combination with methotrexate. For use in adults who have experienced an inadequate response to one or more TNF antagonist therapies. Antibody genetically engineered. Chimeric murine/human monoclonal antibody directed against the CD20 antigen found on surface of B-lymphocytes.
Myones BL, McCurdy D. The antiphospholipid syndrome: immunologic and clinical aspects. Clinical spectrum and treatment. J Rheumatol. 2000 Apr. 27 Suppl 58:20-8. [Medline].
Cuadrado MJ, Hughes GR. Hughes (antiphospholipid) syndrome. Clinical features. Rheum Dis Clin North Am. 2001 Aug. 27(3):507-24, v. [Medline].
Roubey RA. Antiphospholipid antibody syndrome. Koopman's Textbook of Arthritis and Allied Health Conditions. 14th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001. 1546-61.
Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002 Mar 7. 346(10):752-63. [Medline].
Lockshin MD. Antiphospholipid antibody syndrome. Rheum Dis Clin North Am. 1994 Feb. 20(1):45-59. [Medline].
Cimaz R, Descloux E. Pediatric antiphospholipid syndrome. Rheum Dis Clin North Am. 2006 Aug. 32(3):553-73. [Medline].
Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun. 2000 Sep. 15(2):145-51. [Medline].
Welsch S, Branch DW. Antiphospholipid syndrome in pregnancy. Obstetric concerns and treatment. Rheum Dis Clin North Am. 1997 Feb. 23(1):71-84. [Medline].
Hansen KE, Kong DF, Moore KD, Ortel TL. Risk factors associated with thrombosis in patients with antiphospholipid antibodies. J Rheumatol. 2001 Sep. 28(9):2018-24. [Medline].
Harris EN, Pierangeli SS. Equivocal' antiphospholipid syndrome. J Autoimmun. 2000 Sep. 15(2):81-5. [Medline].
Avcin T, Cimaz R, Silverman ED, et al. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics. 2008 Nov. 122(5):e1100-7. [Medline].
Amigo MC, Khamashta MA. Antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. Rheum Dis Clin North Am. 2000 May. 26(2):331-48. [Medline].
Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999 Jul. 42(7):1309-11. [Medline].
Wilson WA, Gharavi AE, Piette JC. International classification criteria for antiphospholipid syndrome: synopsis of a post-conference workshop held at the Ninth International (Tours) aPL Symposium. Lupus. 2001. 10(7):457-60. [Medline].
Lockshin MD, Sammaritano LR, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum. 2000 Feb. 43(2):440-3. [Medline].
Wilson WA. Classification criteria for antiphospholipid syndrome. Rheum Dis Clin North Am. 2001 Aug. 27(3):499-505, v. [Medline].
Miyakis S, Lockshin MD, Atsumi T. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb. 4(2):295-306. [Medline].
[Guideline] Asherson RA, Cervera R, de Groot PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003. 12(7):530-4. [Medline].
Giordano P, Tesse R, Lassandro G, Fracchiolla D, Ranieri P, Lotito A, et al. Clinical and laboratory characteristics of children positive for antiphospholipid antibodies. Blood Transfus. 2011 Dec 22. 1-6. [Medline].
Cook MC. B cell biology, apoptosis, and autoantibodies to phospholipids. Thromb Res. 2004. 114(5-6):307-19. [Medline].
Esmon NL, Safa O, Smirnov MD, Esmon CT. Antiphospholipid antibodies and the protein C pathway. J Autoimmun. 2000 Sep. 15(2):221-5. [Medline].
Meroni PL, Raschi E, Camera M, et al. Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun. 2000 Sep. 15(2):237-40. [Medline].
Meroni PL, Raschi E, Testoni C, et al. Antiphospholipid antibodies and the endothelium. Rheum Dis Clin North Am. 2001 Aug. 27(3):587-602. [Medline].
Rauch J, Subang R, D'Agnillo P, Koh JS, Levine JS. Apoptosis and the antiphospholipid syndrome. J Autoimmun. 2000 Sep. 15(2):231-5. [Medline].
Angles-Cano E, Guillin MC. Antiphospholipid antibodies and the coagulation cascade. Rheum Dis Clin North Am. 2001 Aug. 27(3):573-86. [Medline].
Petri M. Pathogenesis and treatment of the antiphospholipid antibody syndrome. Med Clin North Am. 1997 Jan. 81(1):151-77. [Medline].
Matsuura E, Kobayashi K, Tabuchi M. Accelerated atheroma in the antiphospholipid syndrome. Rheum Dis Clin North Am. 2006 Aug. 32(3):537-51. [Medline].
Horita T, Atsumi T, Yoshida N, Nakagawa H, Kataoka H, Yasuda S. STAT4 single nucleotide polymorphism, rs7574865 G/T, as a risk for antiphospholipid syndrome. Ann Rheum Dis. 2009 Aug. 68(8):1366-7. [Medline].
Pierangeli SS, Vega-Ostertag M, Harris EN. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. Thromb Res. 2004. 114(5-6):467-76. [Medline].
Meroni PL, Raschi E, Testoni C, Tincani A, Balestrieri G, Molteni R, et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum. 2001 Dec. 44(12):2870-8. [Medline].
Ferrara DE, Swerlick R, Casper K, Meroni PL, Vega-Ostertag ME, Harris EN, et al. Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost. 2004 Sep. 2(9):1558-63. [Medline].
Ferrara DE, Liu X, Espinola RG, Meroni PL, Abukhalaf I, Harris EN, et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum. 2003 Nov. 48(11):3272-9. [Medline].
López-Pedrera Ch, Buendía P, Aguirre MA, Velasco F, Cuadrado MJ. Antiphospholipid syndrome and tissue factor: a thrombotic couple. Lupus. 2006. 15(3):161-6. [Medline].
Redecha P, Franzke CW, Ruf W, Mackman N, Girardi G. Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest. 2008 Oct. 118(10):3453-61. [Medline]. [Full Text].
Canaud G, Bienaimé F, Tabarin F, Bataillon G, Seilhean D, Noël LH, et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med. 2014 Jul 24. 371(4):303-12. [Medline].
Skwarecki B. Drug Target Linked to Antiphospholipid Syndrome. Medscape Medical News. Available at http://www.medscape.com/viewarticle/828831. Accessed: January 13, 2015.
Hughson MD, McCarty GA, Brumback RA. Spectrum of vascular pathology affecting patients with the antiphospholipid syndrome. Hum Pathol. 1995 Jul. 26(7):716-24. [Medline].
Asherson RA, Cervera R, Piette JC. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore). 1998 May. 77(3):195-207. [Medline].
Asherson RA, Cervera R, Piette JC. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore). 2001 Nov. 80(6):355-77. [Medline].
Cervera R, Asherson RA, Font J. Catastrophic antiphospholipid syndrome. Rheum Dis Clin North Am. 2006 Aug. 32(3):575-90. [Medline].
Cervera R, Bucciarelli S, Plasin MA, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". J Autoimmun. 2009 May-Jun. 32(3-4):240-5. [Medline].
Asherson RA, Piette JC. The catastrophic antiphospholipid syndrome 1996: acute multi-organ failure associated with antiphospholipid antibodies: a review of 31 patients. Lupus. 1996 Oct. 5(5):414-7. [Medline].
Rosenzweig EB, Widlitz AC, Barst RJ. Pulmonary arterial hypertension in children. Pediatr Pulmonol. 2004 Jul. 38(1):2-22. [Medline].
Moroni G, Ventura D, Riva P. Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis. 2004 Jan. 43(1):28-36. [Medline].
Nochy D, Daugas E, Huong DL, et al. Kidney involvement in the antiphospholipid syndrome. J Autoimmun. 2000 Sep. 15(2):127-32. [Medline].
Amigo MC. Kidney disease in antiphospholipid syndrome. Rheum Dis Clin North Am. 2006 Aug. 32(3):509-22. [Medline].
Daugas E, Nochy D, Huong du LT. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol. 2002 Jan. 13(1):42-52. [Medline].
Garcia-Martin F, De Arriba G, Carrascosa T. Anticardiolipin antibodies and lupus anticoagulant in end-stage renal disease. Nephrol Dial Transplant. 1991. 6(8):543-7. [Medline].
Tektonidou MG, Sotsiou F, Nakopoulou L. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum. 2004 Aug. 50(8):2569-79. [Medline].
Roldan CA, Shively BK, Lau CC, Gurule FT, Smith EA, Crawford MH. Systemic lupus erythematosus valve disease by transesophageal echocardiography and the role of antiphospholipid antibodies. J Am Coll Cardiol. 1992 Nov 1. 20(5):1127-34. [Medline].
Turiel M, Sarzi-Puttini P, Peretti R, et al. Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. Am J Cardiol. 2005 Aug 15. 96(4):574-9. [Medline].
Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation. 1996 Apr 15. 93(8):1579-87. [Medline].
Cervera R. Recent advances in antiphospholipid antibody-related valvulopathies. J Autoimmun. 2000 Sep. 15(2):123-5. [Medline].
Tenedios F, Erkan D, Lockshin MD. Cardiac manifestations in the antiphospholipid syndrome. Rheum Dis Clin North Am. 2006 Aug. 32(3):491-507. [Medline].
Soltész P, Szekanecz Z, Kiss E, Shoenfeld Y. Cardiac manifestations in antiphospholipid syndrome. Autoimmun Rev. 2007 Jun. 6(6):379-86. [Medline].
Yadav D, Chandra J, Sharma S, Singh V. Essential thrombocytosis and antiphospholipid antibody syndrome causing chronic budd-Chiari syndrome. Indian J Pediatr. 2012 Apr. 79(4):538-40. [Medline].
Espinosa G, Cervera R, Font J, Asherson RA. Adrenal involvement in the antiphospholipid syndrome. Lupus. 2003. 12(7):569-72. [Medline].
Brey RL. Differential diagnosis of central nervous system manifestations of the antiphospholipid antibody syndrome. J Autoimmun. 2000 Sep. 15(2):133-8. [Medline].
Frances C, Piette JC. The mystery of Sneddon syndrome: relationship with antiphospholipid syndrome and systemic lupus erythematosus. J Autoimmun. 2000 Sep. 15(2):139-43. [Medline].
Muscal E, Brey RL. Neurologic manifestations of the antiphospholipid syndrome: integrating molecular and clinical lessons. Curr Rheumatol Rep. 2008 Jan. 10(1):67-73. [Medline].
Muscal E, Brey RL. Neurological manifestations of the antiphospholipid syndrome: risk assessments and evidence-based medicine. Int J Clin Pract. 2007 Sep. 61(9):1561-8. [Medline].
Bertolaccini ML, Hughes GR. Antiphospholipid antibody testing: which are most useful for diagnosis?. Rheum Dis Clin North Am. 2006 Aug. 32(3):455-63. [Medline].
Carreras LO, Forastiero RR, Martinuzzo ME. Which are the best biological markers of the antiphospholipid syndrome?. J Autoimmun. 2000 Sep. 15(2):163-72. [Medline].
Derksen RH, de Groot PG. Tests for lupus anticoagulant revisited. Thromb Res. 2004. 114(5-6):521-6. [Medline].
Exner T. Conceptions and misconceptions in testing for lupus anticoagulants. J Autoimmun. 2000 Sep. 15(2):179-83. [Medline].
Galli M. Should we include anti-prothrombin antibodies in the screening for the antiphospholipid syndrome?. J Autoimmun. 2000 Sep. 15(2):101-5. [Medline].
Gilman-Sachs A, Lubinski J, Beer AE, et al. Patterns of anti-phospholipid antibody specificities. J Clin Lab Immunol. 1991 Jun. 35(2):83-8. [Medline].
Mcintyre JA, Wagenknecht DR. Anti-phosphatidylethanolamine (aPE) antibodies: a survey. J Autoimmun. 2000 Sep. 15(2):185-93. [Medline].
Merrill JT. Which antiphospholipid antibody tests are most useful?. Rheum Dis Clin North Am. 2001 Aug. 27(3):525-49. [Medline].
Petri M. Diagnosis of antiphospholipid antibodies. Rheum Dis Clin North Am. 1994 May. 20(2):443-69. [Medline].
Pierangeli SS, Harris EN. Advances in antiphospholipid antibody testing. Clin Appl Immunol Rev. 2000. 1:59-72.
Rapizzi E, Ruffatti A, Tonello M, et al. Correction for age of anticardiolipin antibodies cut-off points. J Clin Lab Anal. 2000. 14(3):87-90. [Medline].
Tincani A, Allegri F, Balestrieri G. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb Res. 2004. 114(5-6):553-8. [Medline].
Tincani A, Balestrieri G, Allegri F, et al. Overview on anticardiolipin ELISA standardization. J Autoimmun. 2000 Sep. 15(2):195-7. [Medline].
Triplett DA. Antiphospholipid-protein antibodies: laboratory detection and clinical relevance. Thromb Res. 1995 Apr 1. 78(1):1-31. [Medline].
Triplett DA. Use of the dilute Russell viper venom time (dRVVT): its importance and pitfalls. J Autoimmun. 2000 Sep. 15(2):173-8. [Medline].
Wong RC. Consensus guidelines for anticardiolipin antibody testing. Thromb Res. 2004. 114(5-6):559-71. [Medline].
Noda S, Ogura M, Tsutsumi A, Udagawa T, Kamei K, Matsuoka K, et al. Thrombotic microangiopathy due to multiple autoantibodies related to antiphospholipid syndrome. Pediatr Nephrol. 2012 Apr. 27(4):681-5. [Medline].
Khamashta MA. Primary prevention of thrombosis in subjects with positive antiphospholipid antibodies. J Autoimmun. 2000 Sep. 15(2):249-53. [Medline].
Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995 Apr 13. 332(15):993-7. [Medline].
Petri M. Management of thrombosis in antiphospholipid antibody syndrome. Rheum Dis Clin North Am. 2001 Aug. 27(3):633-42, viii. [Medline].
Rai R. Obstetric management of antiphospholipid syndrome. J Autoimmun. 2000 Sep. 15(2):203-7. [Medline].
Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005 Nov 17. 353(20):2148-57. [Medline].
Humpl T, Reyes JT, Holtby H. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation. 2005 Jun 21. 111(24):3274-80. [Medline].
Rosenzweig EB, Ivy DD, Widlitz A. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol. 2005 Aug 16. 46(4):697-704. [Medline].
Derksen RH, de Groot PG. Do we Know which Patients with the Antiphospholipid Syndrome Should Receive Long-term High Dose Anti-coagulation?. J Autoimmun. 2000 Sep. 15(2):255-259. [Medline].
Wald DS, Bishop L, Wald NJ, et al. Randomized trial of folic acid supplementation and serum homocysteine levels. Arch Intern Med. 2001 Mar 12. 161(5):695-700. [Medline].
Erkan D, Lockshin MD. New approaches for managing antiphospholipid syndrome. Nat Clin Pract Rheumatol. 2009 Mar. 5(3):160-70. [Medline].
Lockshin M, Tenedios F, Petri M, McCarty G, Forastiero R, Krilis S. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus. 2003. 12(7):518-23. [Medline].
Levine SR, Brey RL, Tilley BC, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004 Feb 4. 291(5):576-84. [Medline].
Belizna CC, Richard V, Thuillez C, Levesque H, Shoenfeld Y. Insights into atherosclerosis therapy in antiphospholipid syndrome. Autoimmun Rev. 2007 Nov. 7(1):46-51. [Medline].
Takemoto CM. Rituximab for ITP: a long-term fix?. Pediatr Blood Cancer. 2009 Feb. 52(2):155-6. [Medline].
Semple JW. ITP three R's: regulation, routing, rituximab. Blood. 2008 Aug 15. 112(4):927-8. [Medline].
Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum. 2005 Oct. 52(10):3168-74. [Medline].
Asherson RA, Chan JK, Harris EN, et al. Anticardiolipin antibody, recurrent thrombosis, and warfarin withdrawal. Ann Rheum Dis. 1985 Dec. 44(12):823-5. [Medline].
Lawrie AS, Purdy G, Mackie IJ, Machin SJ. Monitoring of oral anticoagulant therapy in lupus anticoagulant positive patients with the anti-phospholipid syndrome. Br J Haematol. 1997 Sep. 98(4):887-92. [Medline].
Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med. 1997 Aug 1. 127(3):177-85. [Medline].
Pauzner R, Greinacher A, Selleng K, Althaus K, Shenkman B, Seligsohn U. False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Thromb Haemost. 2009 Jul. 7(7):1070-4. [Medline].
Alarcon-Segovia D, Perez-Ruiz A, Villa AR. Long-term prognosis of antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun. 2000 Sep. 15(2):157-61. [Medline].
Amigo MC. Prognosis in antiphospholipid syndrome. Rheum Dis Clin North Am. 2001 Aug. 27(3):661-9. [Medline].
Erkan D, Asherson RA, Espinosa G, et al. Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis. 2003 Jun. 62(6):530-3. [Medline].